Authors:
Kunal Ahuja, Rohit Vilas Patre
Download free PDF
Prebiotic Fibers Market Size & Share 2026-2035
Report ID: GMI15505
|
Published Date: September 2026
|
Report Format: PDF/Excel/Dashboard/Platform
Download Free PDF
Explore Our Licensing Options:
Download Free PDF
Prebiotic Fibers Market
Get a free sample of this report
What are you hoping to find?
Your PDF is on its way. Tell us little about your research goal, and we'll help you find the most relevant market insights.
Prebiotic Fibers Market Size
The global prebiotic fibers market was valued at USD 6.2 billion in 2025 and is expected to increase from USD 6.6 billion in 2026 to USD 11.6 billion by 2035, at a 6.5% CAGR, according to latest report published by Global Market Insights Inc.
Prebiotic Fibers Market Key Takeaways
Market Leader: Cargill, Incorporated led with over 14.5% market share in 2025.
Leading Players: Top 5 players in this market include Cargill, Incorporated, Archer Daniels Midland (ADM), Ingredion Incorporated, International Flavors & Fragrances (IFF), BENEO GmbH, which collectively held a market share of 56.9% in 2025.
The market covers ingredients that are selectively fermented by gut microbiota and used across food, beverage, supplement, infant, clinical-nutrition, pharmaceutical, and animal-nutrition applications. It includes inulin, fructooligosaccharides (FOS), galactooligosaccharides (GOS), human milk oligosaccharides (HMOs), resistant starch, resistant dextrin, xylooligosaccharides (XOS), polydextrose, lactulose, and other qualifying fibers; it excludes probiotic cultures, finished synbiotic products, and non-fermentable fibers without a documented prebiotic mechanism. [1]International Scientific Association for Probiotics and Prebiotics, nature.com
Revenue rose from USD 5.3 billion in 2022 to USD 6.2 billion in 2025, representing an approximately 5.4% historic CAGR. Volume is estimated at about 1,630 kilo tons in 2025 and 2,620 kilo tons in 2035, or approximately 4.8% growth annually. The difference between revenue and volume growth reflects a mix shift toward higher-value oligosaccharides rather than a simple expansion in bulk-fiber consumption. Market estimates combine demand across end users with revenue reconciliation to product mix and reported market anchors. [2]Global Market Insights Inc., gminsights.com
The market is defined in revenue terms as USD billion and volume terms as kilo tons. The historic period is 2022-2025, with 2025 as the base year, and the forecast period is 2026-2035. The commercial value of a prebiotic is determined by more than fiber content: solubility, process stability, dose tolerance, labeling treatment, and evidence supporting a specific application determine whether a formulation can support a premium price.
GMI Analyst View
The central commercial divide is between scalable fibers that solve several formulation problems at once and specialty structures whose value depends on regulatory access and application-specific evidence. Inulin retains the broadest addressable base because it can add fiber, replace fat or sugar in selected systems, and fit established industrial supply chains. HMOs and selected GOS grades, by contrast, are used at lower volumes but can command more value where infant and clinical nutrition manufacturers pay for biological specificity, documentation, and tightly controlled supply.
The forecast therefore depends less on a uniform rise in "gut health" demand than on manufacturers' ability to translate microbiome positioning into repeat-purchase formats. Suppliers that pair a clinically differentiated ingredient with process support will be better placed than suppliers selling undifferentiated fiber powder. The near-term constraint is not raw consumer interest; it is whether the ingredient can meet dose, sensory, tolerance, and claim requirements within the target product's cost envelope.
Key Drivers
Consumer interest in digestive wellness supports the market when it converts into routine purchase occasions rather than occasional supplement use. This favors ingredients that can enter cereals, dairy, snack bars, and beverage systems without compromising texture or taste. The operational effect is broader demand for soluble, neutral-tasting grades and formulation support that lowers reformulation risk.
FDA recognition of certain isolated or synthetic non-digestible carbohydrates as dietary fiber, including inulin and FOS under the applicable framework, improves the commercial rationale for inclusion in U.S. foods. Manufacturers can use a single ingredient to address fiber-enrichment targets and digestive-wellness positioning, expanding the addressable applications beyond dedicated supplements. [3]U.S. Food and Drug Administration, fda.gov
HMO commercialization is increasingly tied to infant-formula innovation rather than commodity fiber demand. dsm-firmenich reported 2025 approvals for GLYCARE® 2'FL and LNnT in China and for GLYCARE® 2'FL in India, creating a regulatory route into two large infant-nutrition markets. The immediate implication is a longer qualification cycle but greater supplier stickiness once a formula specification is approved. [4]dsm-firmenich, annualreport.dsm-firmenich.com
Key Restraints
Novel prebiotic structures can be commercially compelling but remain difficult to move into mass-market formulations when fermentation, purification, and regulatory costs are high. This narrows early adoption to infant, clinical, and premium supplement applications, where the formulation benefit can support a higher ingredient bill. Scale and process improvements are needed before specialty fibers can displace bulk inulin in high-volume products.
Regulatory fragmentation increases the cost of commercialization because an ingredient's safety status, permitted use level, and health-claim treatment can vary across markets. The resulting burden is material for brands running regional product platforms: they may need different labeling, dossiers, or formulations, reducing the scale benefits of a single global launch.
Tolerance is a formulation constraint, not merely a consumer-education issue. Higher inclusions of fermentable fibers can create gastrointestinal discomfort for some consumers, limiting the dose that can be used in an everyday food. Suppliers that improve efficacy per gram, blend complementary fibers, or provide substantiated dose guidance can protect repeat purchase and reduce reformulation risk.
GMI Analyst View
Drivers and restraints point toward selective premiumization rather than a wholesale replacement of conventional fiber systems. Regulatory recognition and consumer demand provide a broad demand floor, but tolerance and cost determine which fibers can move into high-frequency, mass-market formats. Inulin and FOS benefit first because they combine recognized functionality with mature process economics. Specialty suppliers gain where the customer's economics are governed by formula differentiation or clinical positioning, not cost per kilogram.
The likely winners are ingredient companies that can reduce the buyer's qualification burden. Regulatory dossiers, application labs, and reliable delivery are commercially linked: together they shorten the interval between an ingredient selection and a successful launch. That advantage is most valuable in infant nutrition and multinational food platforms, where switching after approval is expensive.
Prebiotic Fibers Market Segment Analysis
By Product Type
Inulin generated USD 2.44 billion in 2025, equal to 39.4% of market revenue, and is projected to reach USD 4.8 billion by 2035 at a 7.0% CAGR. Its scale stems from a mature chicory-based supply chain and its ability to provide fiber enrichment, texture, and selected sugar- or fat-replacement functions. FOS contributed USD 0.92 billion (14.8%) and is projected to reach USD 1.6 billion at a 5.7% CAGR; its established use profile supports broad food and supplement demand, but its growth is moderated by maturity and substitution in premium applications.
GOS was valued at USD 1.1 billion in 2025 and is forecast to reach USD 2.1 billion at a 6.7% CAGR. Its importance in infant and adult digestive-health products supports higher value density than commodity fibers. HMOs, at USD 0.38 billion in 2025, are projected to reach USD 0.8 billion at a 7.7% CAGR, making them the fastest-growing major product type; their commercial ceiling is set by regulatory approvals and formula qualification rather than bulk throughput.
Resistant starch generated USD 316.6 million in 2025 and is projected to reach USD 0.62 billion at an approximately 6.9% CAGR. Resistant dextrin totaled USD 145 million and is expected to reach USD 0.28 billion at about 6.8% CAGR. Both are positioned where digestive functionality must coexist with familiar food-processing performance. XOS accounted for USD 90.6 million and is expected to reach USD 0.19 billion at 7.6% CAGR, while polydextrose and lactulose start at USD 200 million and USD 120 million, respectively, and remain more application-specific. The USD 487.4 million "others" category is expected to reach USD 0.70 billion, but fragmented supplier bases and less standardized demand will limit its strategic influence.
By Form
Powder was the dominant form, representing 63.9% of 2025 revenue and projected to exceed USD 7.1 billion by 2035 at a 6.0% CAGR. It fits dry blending, tablet and sachet production, and bulk industrial handling, preserving its role as the market's principal volume platform. Liquid/syrup accounted for 23.1% in 2025 and is estimated to grow at 7.5% CAGR to USD 2.95 billion as ready-to-drink beverages, dairy, and liquid infant nutrition value immediate dispersibility.
Granules produced USD 414.7 million in 2025 (6.7%) and are projected to reach USD 0.71 billion at 5.5% CAGR. Their role is concentrated in controlled-flow, single-serve, and low-moisture applications. Capsules/tablets contributed USD 391.9 million (6.3%) and are expected to reach USD 0.77 billion at a 7.0% CAGR, reflecting the consumer preference for dose-controlled supplement formats.
By End User
Dietary supplements generated USD 1.72 billion in 2025, or 27.7% of the market, and are projected to reach USD 3.39 billion at a 7.0% CAGR. The segment monetizes named ingredients and dosage precision more readily than embedded food applications. Dairy products held 11.0% of revenue and grow at 5.6% CAGR, while bakery and confectionery generated USD 663.6 million and grow at 6.8% CAGR, supported by fiber enrichment and texture management.
Beverages generated an estimated USD 650 million in 2025 and are projected to reach USD 1.26 billion at a 6.9% CAGR. Infant nutrition, at an estimated USD 550 million, is expected to reach USD 0.98 billion at 6.0% CAGR; higher-value HMO and GOS additions make regulatory clearance and supply continuity decisive. Cereals and snack bars totaled USD 414.7 million and grow at 7.0% CAGR, while processed foods are expected to grow at 6.9% CAGR as manufacturers incorporate fiber into familiar convenience formats.
Pharmaceuticals generated USD 240.5 million in 2025 and are estimated to grow at 7.2% CAGR; clinical nutrition generated USD 132.7 million and grows at 6.5% CAGR. These channels reward dose control, documentation, and tolerance management. Poultry feed, swine feed, ruminant feed, aquaculture, and pet food together represented an estimated USD 670 million in 2025. Pet food is the fastest-growing feed-related end user at an estimated 7.5% CAGR, while poultry, swine, ruminant, and aquaculture applications are expected to grow at approximately 5.5%, 5.0%, 4.5%, and 5.8%, respectively.
GMI Analyst View
Incremental value will concentrate where ingredients solve a measurable formulation or positioning problem. Powder remains indispensable because it is the least disruptive route into existing industrial lines, but liquid formats should capture a disproportionate share of innovation in beverages and dairy. The higher-growth applications are not automatically the largest: HMOs, capsules/tablets, infant nutrition, and clinical channels trade scale for qualification intensity and price resilience.
Inulin will remain the value anchor, but it does not define the market's margin pool. A more differentiated opportunity lies in connecting specialty oligosaccharides to applications that can justify documentation, clinical support, and controlled supply. That shifts competition from raw material availability toward the ability to deliver a validated system.
Prebiotic Fibers Market Regional Analysis
North America was the largest regional market at USD 2.3 billion in 2025 (37.1%) and is projected to reach USD 3.82 billion by 2035 at a 5.2% CAGR. FDA dietary-fiber recognition gives food manufacturers a defined labeling pathway for inulin and FOS, while a mature supplement channel supports premium, named-ingredient products. The region's growth is slower than Asia Pacific because its application base is more established, yet its customer concentration and formulation infrastructure make it central to supplier qualification strategy.
Europe generated USD 2.0 billion in 2025 (32.2%) and is projected to reach USD 3.42 billion at a 5.5% CAGR. The region combines strong demand in bakery, dairy, and processed foods with a major chicory-processing base in Belgium, the Netherlands, and France. Labeling and claim requirements raise commercialization complexity, but that complexity also favors established suppliers with traceable sourcing, sustainability credentials, and technical support.
Asia Pacific accounted for USD 1.33 billion in 2025 (21.5%) and is forecast to reach USD 3.19 billion at a 9.2% CAGR, the fastest among the major regions. China, Japan, and India combine expanding functional-food, supplement, and infant-nutrition demand with increasingly actionable regulatory pathways. dsm-firmenich's China and India HMO approvals and ITOCHU's 2025 agreement for exclusive Japanese marketing rights to Sensus inulin illustrate how approvals and distribution partnerships can turn regional demand into a local commercial position. [5]ITOCHU Corporation, itochu.co.jp
Latin America represented USD 341 million in 2025 (5.5%) and is expected to reach USD 0.70 billion at an estimated 7.5% CAGR. Brazil and Mexico are the principal demand centers, where supplement adoption and food-and-beverage fortification support growth. The decisive commercial factor is affordable, reliable supply rather than highly specialized product architecture, making distributor reach and formulation economics important.
Middle East & Africa totaled USD 229 million in 2025 (3.7%) and is projected to reach USD 0.49 billion at an estimated 7.8% CAGR. Saudi Arabia, the UAE, and South Africa provide the principal platforms for premium supplements, infant nutrition, and functional foods. The region's smaller base increases percentage growth, but import dependence and country-by-country registration will continue to determine the pace at which demand becomes recurring volume.
GMI Analyst View
North America and Europe will remain the market's revenue and application-development centers, but Asia Pacific will determine a growing share of incremental demand and specialty-fiber commercialization. The regional divergence is structural: mature markets reward evidence, traceability, and broad application support, whereas growth markets require successful regulatory translation and local route-to-market execution.
A supplier's regional position will increasingly be defined by its ability to combine a global ingredient platform with market-specific documentation and partners. The ITOCHU-Sensus arrangement is a useful example: access to an established Japanese channel can be as commercially important as production capacity. In Asia Pacific, regulatory authorization for HMOs may create a similarly durable advantage because infant formula specifications are not easily switched once qualified.
Prebiotic Fibers Market Share & Competitive Landscape
The market is moderately concentrated. Cargill held a 14.5% share in 2025, while Cargill, ADM, Ingredion, IFF, and BENEO together held 56.9%. Scale matters in chicory sourcing, manufacturing, technical support, and multinational customer access; however, specialty GOS and HMO suppliers retain defensible positions where clinical evidence or regulatory approvals matter more than portfolio breadth.
Cosucra Groupe Warcoing SA markets FIBRULINE™ inulin and FIBRULOSE™ oligofructose from chicory. Its differentiation is dedicated chicory-fiber specialization and European sourcing, which suits buyers seeking a focused supplier rather than a broad commodity-ingredient platform.
BENEO GmbH supplies Orafti® Inulin and Orafti® Oligofructose for food, feed, and nutrition applications. Its integrated chicory platform, application expertise, and sustainability positioning reinforce its role among the leading suppliers; Thai FDA approval for an exclusive prebiotic claim on Orafti® Inulin in September 2025 strengthens its access to Southeast Asian functional-food customers.
Cargill Incorporated is the market leader, with a 14.5% share in 2025. Its Oliggo-Fiber® range and broad food-ingredient platform provide procurement scale, global distribution, and cross-category formulation access, allowing prebiotic fibers to be sold as part of wider nutrition and reformulation programs rather than as a standalone input.
Clasado Biosciences Ltd. focuses on Bimuno® GOS. Its competitive position rests on clinical differentiation and branded GOS positioning, which are particularly relevant in dietary supplements and digestive-health products where buyers value evidence tied to a specific ingredient profile.
Ingredion Incorporated addresses multiple fiber needs through NUTRAFLORA® scFOS, HI-MAIZE® and NOVELOSE® resistant starches, and VERSAFIBE™. This range gives customers alternatives across process conditions and sensory targets, making Ingredion a broad formulation partner rather than a single-fiber supplier.
Yakult Pharmaceutical Industry supplies OLIGOMATE® GOS in powder and syrup formats. Its position is strongest in Japan and other Asia Pacific markets, where its ties to dairy and infant-nutrition channels help convert GOS science into application-specific demand.
Roquette Frères markets NUTRIOSE® soluble fiber, primarily a resistant-dextrin platform. Its advantage lies in application versatility and digestive-tolerance positioning across beverages, dairy, confectionery, bakery, and supplements.
dsm-firmenich AG supplies eight commercially available GLYCARE® HMO structures. The portfolio's breadth, fermentation heritage, and 2025 China and India regulatory milestones differentiate the company in the highest-value prebiotic niche, where regulatory coverage and formula qualification create meaningful switching costs. [6]dsm-firmenich, dsm-firmenich.com
Tate & Lyle PLC combines PROMITOR® soluble fiber with EUOLIGO® FOS and GOSYAN® GOS, added through its 2022 Quantum Hi-Tech acquisition. The combination broadens its offering across resistant dextrin, FOS, and GOS and strengthens its access to Asian functional-food and infant-nutrition applications.
Cosun Ingredients B.V. / Sensus BV supplies Frutafit® inulin and Frutalose® oligofructose. ITOCHU described Sensus as holding the second-largest share of the global inulin market when it secured exclusive Japanese marketing rights for INULIA® in June 2025. Its natural chicory-fiber positioning and liquid as well as powder FOS capability differentiate it in applications requiring both fiber functionality and soluble processing performance.
Major players operating in the prebiotic fibers market include:
Recent Industry Developments
Need a specific section of this report?
Purchase regional analysis, country-level analysis, company profiles, or any other segment-level insights separately
based on your research needs.
Frequently Asked Question(FAQ) :
Research methodology, data sources & validation process
This report draws on a structured research process built around direct industry conversations, proprietary modelling, and rigorous cross-validation and not just desk research.
Our 6-step research process
1. Research design & analyst oversight
At GMI, our research methodology is built on a foundation of human expertise, rigorous validation, and complete transparency. Every insight, trend analysis, and forecast in our reports is developed by experienced analysts who understand the nuances of your market.
Our approach integrates extensive primary research through direct engagement with industry participants and experts, complemented by comprehensive secondary research from verified global sources. We apply quantified impact analysis to deliver dependable forecasts, while maintaining complete traceability from original data sources to final insights.
2. Primary research
Primary research forms the backbone of our methodology, contributing nearly 80% to overall insights. It involves direct engagement with industry participants to ensure accuracy and depth in analysis. Our structured interview program covers regional and global markets, with inputs from C-suite executives, directors, and subject matter experts. These interactions provide strategic, operational, and technical perspectives, enabling well-rounded insights and reliable market forecasts.
3. Data mining & market analysis
Data mining is a key part of our research process, contributing nearly 20% to the overall methodology. It involves analysing market structure, identifying industry trends, and assessing macroeconomic factors through revenue share analysis of major players. Relevant data is collected from both paid and unpaid sources to build a reliable database. This information is then integrated to support primary research and market sizing, with validation from key stakeholders such as distributors, manufacturers, and associations.
4. Market sizing
Our market sizing is built on a bottom-up approach, starting with company revenue data gathered directly through primary interviews, alongside production volume figures from manufacturers and installation or deployment statistics. These inputs are then pieced together across regional markets to arrive at a global estimate that stays grounded in actual industry activity.
5. Forecast model & key assumptions
Every forecast includes explicit documentation of:
✓ Key growth drivers and their assumed impact
✓ Restraining factors and mitigation scenarios
✓ Regulatory assumptions and policy change risk
✓ Technology adoption curve parameter
✓ Macroeconomic assumptions (GDP growth, inflation, currency)
✓ Competitive dynamics and market entry/exit expectations
6. Validation & quality assurance
The final stages involve human validation, where domain experts manually review filtered data to identify nuances and contextual errors that automated systems might miss. This expert review adds a critical layer of quality assurance, ensuring data aligns with research objectives and domain-specific standards.
Our triple-layer validation process ensures maximum data reliability:
✓ Statistical Validation
✓ Expert Validation
✓ Market Reality Check
Trust & credibility
Verified data sources
Trade publications
Industry journals, trade publications, and specialized media.
Industry databases
Proprietary and third-party market databases
Regulatory filings
Government procurement records and policy documents
Academic research
University studies and specialist institution reports
Company reports
Annual reports, investor presentations, and filings
Expert interviews
C-suite, procurement leads, and technical specialists
GMI archive
13,000+ published studies across 20+ industry verticals
Trade data
Import/export volumes, HS codes, and customs records
Parameters studied & evaluated
Every data point in this report is validated through primary interviews, true bottom-up modelling, and rigorous cross-checks. Read about our research process →